Innovating Works

B-Path

Financiado
Breath Pathogen Detection (B-Path): Establishing Exhaled Breath Aerosol (XBA) sa...
Breath Pathogen Detection (B-Path): Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening of respiratory infections Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses. Despite the importance of early detection for individual health and pande... Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses. Despite the importance of early detection for individual health and pandemic control, flawed sampling methods for respiratory infections limit the impact of highly-sensitive diagnostics. The B-Path project will tackle this problem by establishing exhaled breath aerosol (XBA) as an evidence-based, non-invasive sample for simple detection of respiratory infections that can be undertaken at all levels of care. We will achieve this by developing and optimising two innovative, easy-to-use and scalable XBA sampling devices and generating evidence for their use in diagnosis and screening (for early diagnosis and transmission control). We will use different model pathogens that have caused epidemics and pandemics globally – SARS-CoV-2, influenza, and tuberculosis (TB) – and we will generate data on the feasibility of multiplex detection of respiratory pathogens in XBA samples, the adaptability to novel pathogens applying viral metagenomics, and point-of-care testing with lateral-flow assays. We will assess the sampling efficiency of the novel devices against a benchmark Respiratory Aerosol Sampling Chamber and evaluate performance, feasibility, and acceptability, in comparison to the current standard of sampling in multi-country clinical studies of diagnosis and screening. Impact and economic modelling will inform the implementation potential of the novel devices for the different use cases and help assess trade-offs. The project will leverage innovation in bioaerosol and material science, as well as the multidisciplinary (including academia, industry and NGOs) consortium’s track record of delivering transformative diagnostic innovation. We envision that a single breath sample enables accessible and accurate detection of highly transmissible respiratory infections, thereby improving both individual and population health. ver más
30/06/2028
UKHD
3M€
Duración del proyecto: 54 meses Fecha Inicio: 2023-12-11
Fecha Fin: 2028-06-30

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-11
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-HLTH-2023-TOOL-05-08: Pandemic preparedness and response: In vitro diagnostic devices to tackle cross-border health threats
Cerrada hace 1 año
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
UNIVERSITATSKLINIKUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5